183 related articles for article (PubMed ID: 9222071)
1. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
[TBL] [Abstract][Full Text] [Related]
2. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
Seifert H
Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
[TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
Coque TM; Singh KV; Murray BE
J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
8. Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.
Rafay AM
Saudi Med J; 2001 Mar; 22(3):238-43. PubMed ID: 11307110
[TBL] [Abstract][Full Text] [Related]
9. Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.
Gradelski E; Valera L; Kolek B; Bonner D; Fung-Tomc J
Int J Antimicrob Agents; 2001 Jul; 18(1):43-8. PubMed ID: 11463525
[TBL] [Abstract][Full Text] [Related]
10. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.
Shonekan D; Handwerger S; Mildvan D
J Antimicrob Chemother; 1997 Mar; 39(3):405-9. PubMed ID: 9096191
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
Endtz HP; Mouton JW; den Hollander JG; van den Braak N; Verbrugh HA
Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
[TBL] [Abstract][Full Text] [Related]
12. Comparison of in vitro activity of trovafloxacin against gram-positive and gram-negative organisms with quinolones and beta-lactam antimicrobial agents.
Dembry LM; Roberts JC; Schock KD; Marino SP; Farrel PA; Andriole VT
Diagn Microbiol Infect Dis; 1998 May; 31(1):301-11. PubMed ID: 9597391
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
Felmingham D; Robbins MJ; Ingley K; Mathias I; Bhogal H; Leakey A; Ridgway GL; Grüneberg RN
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates.
Verbist L; Verhaegen J
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):683-5. PubMed ID: 8894581
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
Ling TK; Liu EY; Cheng AF
Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
[TBL] [Abstract][Full Text] [Related]
17. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
Tali-Maamar H; Tebbal S; Rahal K
Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.
Kerawala M; Ambler JE; Lee PY; Drabu YJ
Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):271-5. PubMed ID: 11399019
[TBL] [Abstract][Full Text] [Related]
19. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
Pechère JC; Gootz TD
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
